StockNews.AI
ZEAL
StockNews.AI
152 days

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

1. Zealand Pharma increases share capital by DKK 27,425 via employee warrants. 2. Total proceeds from capital increase are approximately DKK 3.5 million. 3. New shares will be listed on Nasdaq Copenhagen post-registration. 4. Warrants provide rights to dividends and voting at general meetings. 5. Zealand focuses on peptide-based medicines with multiple drug candidates.

5m saved
Insight
Article

FAQ

Why Neutral?

The capital increase is modest and driven by employee incentives, limiting immediate market impact.

How important is it?

While the capital increase is significant for corporate structuring, it is routine and minor in scale.

Why Short Term?

The effects of this capital increase are likely to be felt quickly but are not long-lasting.

Related Companies

N/A
March 20, 2025 12:00 ET  | Source: Zealand Pharma Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme. Each warrant gives the owner the right to subscribe for one newly issued Zealand Pharma share at a prespecified exercise price within the specific predefined time periods before expiration in the warrant programs. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com. The exercise price was DKK 224.40 per share for 7,917 of new shares and DKK 90.70 per share for 19,508 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 3,545,950.40. The new shares give rights to dividends and other rights from the time of the respective warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma’s general meetings. Zealand Pharma has only one class of shares. The new shares will be admitted to trading on Nasdaq Copenhagen after the capital increase has been registered with the Danish Business Authority. Following registration of the capital increase with the Danish Business Authority, the share capital of Zealand Pharma will be nominally DKK 71,051,296 divided into 71,051,296 shares with a nominal value of DKK 1 each and corresponding to a total of 71,051,296 votes. A full copy of the new and amended Articles of Association can be found at https://www.zealandpharma.com once registered with the Danish Business Authority. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. ContactAnna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@zealandpharma.com Adam Lange (Investors)Investor Relations OfficerZealand PharmaEmail: alange@zealandpharma.com Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com

Related News